House dust mite allergen tablets in allergic rhinitis

Phase 2, randomised, double-blind trial of House dust mite allergen extract in allergic rhinitis (AR) (4 arms), sponsored by Stallergenes Greer. Primary endpoint: Change From Baseline to the End-of-treatment Period in the Area Under the Curve of the Rhinitis Total Symptom Score Recorded During 4 Hours (0-4h) of the Allergen Challenge at 6 months. Started Dec 2010; status: completed.